173 related articles for article (PubMed ID: 35892881)
1. Diagnostic Models Combining Clinical Information, Ultrasound and Biochemical Markers for Ovarian Cancer: Cochrane Systematic Review and Meta-Analysis.
Davenport CF; Rai N; Sharma P; Deeks J; Berhane S; Mallett S; Saha P; Solanki R; Bayliss S; Snell K; Sundar S
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892881
[TBL] [Abstract][Full Text] [Related]
2. Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women.
Davenport C; Rai N; Sharma P; Deeks JJ; Berhane S; Mallett S; Saha P; Champaneria R; Bayliss SE; Snell KI; Sundar S
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD011964. PubMed ID: 35879201
[TBL] [Abstract][Full Text] [Related]
3. Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis.
Westwood M; Ramaekers B; Lang S; Grimm S; Deshpande S; de Kock S; Armstrong N; Joore M; Kleijnen J
Health Technol Assess; 2018 Aug; 22(44):1-264. PubMed ID: 30165935
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of IOTA Simple Rules, IOTA ADNEX Model, RMI, and Subjective Assessment for Preoperative Adnexal Mass Evaluation: The Experience of a Tertiary Care Referral Hospital.
Vilendecic Z; Radojevic M; Stefanovic K; Dotlic J; Likic Ladjevic I; Dugalic S; Stefanovic A
Gynecol Obstet Invest; 2023; 88(2):116-122. PubMed ID: 36716716
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of HE4, CA-125, Risk of Ovarian Malignancy Algorithm (ROMA) and Risk of Malignancy Index (RMI) in the Preoperative Assessment of Patients with Adnexal Mass.
Al Musalhi K; Al Kindi M; Al Aisary F; Ramadhan F; Al Rawahi T; Al Hatali K; Mula-Abed WA
Oman Med J; 2016 Sep; 31(5):336-44. PubMed ID: 27602187
[TBL] [Abstract][Full Text] [Related]
6. Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.
Chacón E; Dasí J; Caballero C; Alcázar JL
Gynecol Obstet Invest; 2019; 84(6):591-598. PubMed ID: 31311023
[TBL] [Abstract][Full Text] [Related]
7. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods.
Meys EMJ; Jeelof LS; Achten NMJ; Slangen BFM; Lambrechts S; Kruitwagen RFPM; Van Gorp T
Ultrasound Obstet Gynecol; 2017 Jun; 49(6):784-792. PubMed ID: 27514486
[TBL] [Abstract][Full Text] [Related]
8. Performance of IOTA Simple Rules Risks, ADNEX Model, Subjective Assessment Compared to CA125 and HE4 with ROMA Algorithm in Discriminating between Benign, Borderline and Stage I Malignant Adnexal Lesions.
Czekierdowski A; Stachowicz N; Smolen A; Łoziński T; Guzik P; Kluz T
Diagnostics (Basel); 2023 Feb; 13(5):. PubMed ID: 36900029
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the ADNEX and ROMA risk prediction models for the diagnosis of ovarian cancer: a multicentre external validation in patients who underwent surgery.
Landolfo C; Ceusters J; Valentin L; Froyman W; Van Gorp T; Heremans R; Baert T; Wouters R; Vankerckhoven A; Van Rompuy AS; Billen J; Moro F; Mascilini F; Neumann A; Van Holsbeke C; Chiappa V; Bourne T; Fischerova D; Testa A; Coosemans A; Timmerman D; Van Calster B
Br J Cancer; 2024 Apr; 130(6):934-940. PubMed ID: 38243011
[TBL] [Abstract][Full Text] [Related]
12. Discriminative value of CA-125, HE4, Risk of Malignancy Index II (RMI-II) and Risk of Malignancy Algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral Centre in Portugal.
Melo Â; Veríssimo R; Farinha M; Martins NN; Martins FN
J Obstet Gynaecol; 2018 Nov; 38(8):1140-1145. PubMed ID: 29884096
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. [Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity].
Krascsenits G; Balázs B; Dudnyikova A; Purcsi K; Orosz E; Pete I
Magy Onkol; 2016 Nov; 60(4):320-327. PubMed ID: 27898751
[TBL] [Abstract][Full Text] [Related]
15. Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study.
Van Calster B; Valentin L; Froyman W; Landolfo C; Ceusters J; Testa AC; Wynants L; Sladkevicius P; Van Holsbeke C; Domali E; Fruscio R; Epstein E; Franchi D; Kudla MJ; Chiappa V; Alcazar JL; Leone FPG; Buonomo F; Coccia ME; Guerriero S; Deo N; Jokubkiene L; Savelli L; Fischerová D; Czekierdowski A; Kaijser J; Coosemans A; Scambia G; Vergote I; Bourne T; Timmerman D
BMJ; 2020 Jul; 370():m2614. PubMed ID: 32732303
[TBL] [Abstract][Full Text] [Related]
16. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Yanaranop M; Anakrat V; Siricharoenthai S; Nakrangsee S; Thinkhamrop B
Gynecol Obstet Invest; 2017; 82(1):47-53. PubMed ID: 27197526
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the risk of malignancy in adnexal masses: validation of O-RADS and comparison with ADNEX model, SA, and RMI.
Wang R; Yang Z
Ginekol Pol; 2023; 94(10):799-806. PubMed ID: 36929789
[TBL] [Abstract][Full Text] [Related]
18. Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis.
Wynants L; Timmerman D; Verbakel JY; Testa A; Savelli L; Fischerova D; Franchi D; Van Holsbeke C; Epstein E; Froyman W; Guerriero S; Rossi A; Fruscio R; Leone FP; Bourne T; Valentin L; Van Calster B
Clin Cancer Res; 2017 Sep; 23(17):5082-5090. PubMed ID: 28512173
[No Abstract] [Full Text] [Related]
19. Sonographic Assessment of Complex Ultrasound Morphology Adnexal Tumors in Pregnant Women with the Use of IOTA Simple Rules Risk and ADNEX Scoring Systems.
Czekierdowski A; Stachowicz N; Smoleń A; Kluz T; Łoziński T; Miturski A; Kraczkowski J
Diagnostics (Basel); 2021 Feb; 11(3):. PubMed ID: 33671023
[TBL] [Abstract][Full Text] [Related]
20. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China.
Chen H; Qian L; Jiang M; Du Q; Yuan F; Feng W
Ultrasound Obstet Gynecol; 2019 Dec; 54(6):815-822. PubMed ID: 31152572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
